Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319042 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL9632303 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL198090 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL5317333 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL200766 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| Iodide SCHEMBL9630545 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL7561213 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL16990768 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL9632302 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Iodide SCHEMBL9630733 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | claimed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246607-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2024-12-05 | — | — | WO | claimed |
| WO-2024196901-A2 | A HIGH THROUGHPUT ION-SENSING METHOD | WHITESIDES GEORGE M (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024196902-A2 | COUPLING OPTICAL AND POTENTIOMETRIC MEASUREMENTS WITH MAGNETIC LEVITATION | WHITESIDES GEORGE M (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4226918-A1 | PHARMACEUTICAL SINGLE DOSAGE FORM FOR ORAL DELIVERY OF PEPTIDES | Majewski, Filip (PL) | 2023-08-16 | — | — | EP | claimed |
| US-20160339081-A1 | Peptide Pharmaceutical for Oral Delivery | UNIGENE LABORATORIES INC. | 2016-11-24 | — | — | US | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | claimed |
| US-4963556-A | ANTIVIRAL AGENTS | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| US-4835138-A | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO., INC. (US) | 1989-05-30 | — | — | US | claimed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | claimed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | claimed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SLC10A2, SLC5A7, SLC18A3 | CES2 156/4885MAPK1 3672/4885CYP1A2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.